Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70087 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Mita Kuchimanchi und 17 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Waltham, MA, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline foundation.
Abstract (Originalsprache)
Dostarlimab in combination with carboplatin–paclitaxel was approved for primary advanced or recurrent endometrial cancer (pA/rEC). The first interim analysis (IA1) of RUBY Part 1 (NCT03981796) showed no significant exposure–response (ER) relationship for progression‐free survival or for the five most common dostarlimab‐related adverse events (AEs), except rash. Herein, we report the ER relationship between dostarlimab exposure and overall survival (OS) and between dostarlimab exposure and dostarlimab‐related AEs. Population pharmacokinetic model was based on IA1, and the predicted exposure metrics from Cycle 1 were used to perform ER analysis at the second interim analysis (IA2). AE analysis was completed for three periods: Cycles 1‐6 (chemotherapy phase), Cycle 7 and beyond (monotherapy phase), and all cycles. Included in the OS analysis were 232 patients treated with dostarlimab + carboplatin–paclitaxel. Cox regression of OS showed no significant ER relationship based on dostarlimab Cycle 1 exposure, except for rash and arthralgia. The increase in predicted probabilities for rash and arthralgia for patients with high versus low exposure was limited, ranging from 5.6% to 10.4% for rash and 4.3% to 17.7% for arthralgia (deemed not clinically relevant). These data support the risk/benefit profile at the selected dose of dostarlimab + carboplatin–paclitaxel as standard of care in patients with pA/rEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Waltham, MA, USA.
- Department of Oncology, Odense University Hospital, Odense, Denmark.
- qPharmetra, Uppsala, Sweden.
- Fox Chase Cancer Center, Philadelphia, PA, USA.
- Chernihiv Medical Center of Modern Oncology, Chernihiv Regional Council, Chernihiv, Ukraine.
- Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, PA, USA.
Förderung
- GSK
- GlaxoSmithKline foundation
Zitieren
APA
Kuchimanchi, M., Jørgensen, T. L., Hanze, E., Jain, A., Alskär, O., Zub, O., Shahin, M. S., Koliadi, A., Pothuri, B., Krivak, T., Pishchyk, M., Segev, Y., Backes, F. J., Gennigens, C., Bouberhan, S., Zajic, S., Melhem, M., & Buscema, J. (2026). Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70087
Vancouver
Kuchimanchi M, Jørgensen TL, Hanze E, Jain A, Alskär O, Zub O, et al. Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70087
BibTeX
@article{Kuchimanchi2026,
author = {Kuchimanchi, Mita and Jørgensen, Trine Lembrecht and Hanze, Eva and Jain, Angela and Alskär, Oskar and Zub, Oleksandr and Shahin, Mark S and Koliadi, Anthoula and Pothuri, Bhavana and Krivak, Thomas and Pishchyk, Mikalai and Segev, Yakir and Backes, Floor J and Gennigens, Christine and Bouberhan, Sara and Zajic, Stefan and Melhem, Murad and Buscema, Joseph},
title = {Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70087}
}
EUVIMED